S&P 500   3,570.70 (+0.37%)
DOW   29,518.92 (+0.87%)
QQQ   290.21 (-0.06%)
AAPL   114.71 (-2.24%)
MSFT   209.97 (-0.20%)
FB   268.42 (-0.47%)
GOOGL   1,725.28 (-0.64%)
AMZN   3,102.18 (+0.09%)
TSLA   519.68 (+6.14%)
NVDA   526.36 (+0.54%)
BABA   270.70 (-0.01%)
CGC   24.74 (+4.30%)
GE   10.13 (+3.79%)
MU   63.90 (+4.07%)
AMD   85.85 (+1.43%)
T   28.53 (+0.74%)
NIO   54.15 (+9.95%)
F   8.87 (+1.49%)
ACB   7.27 (+1.96%)
GILD   59.45 (-1.10%)
NFLX   482.10 (-1.26%)
BA   209.39 (+4.89%)
DIS   146.15 (+3.60%)
S&P 500   3,570.70 (+0.37%)
DOW   29,518.92 (+0.87%)
QQQ   290.21 (-0.06%)
AAPL   114.71 (-2.24%)
MSFT   209.97 (-0.20%)
FB   268.42 (-0.47%)
GOOGL   1,725.28 (-0.64%)
AMZN   3,102.18 (+0.09%)
TSLA   519.68 (+6.14%)
NVDA   526.36 (+0.54%)
BABA   270.70 (-0.01%)
CGC   24.74 (+4.30%)
GE   10.13 (+3.79%)
MU   63.90 (+4.07%)
AMD   85.85 (+1.43%)
T   28.53 (+0.74%)
NIO   54.15 (+9.95%)
F   8.87 (+1.49%)
ACB   7.27 (+1.96%)
GILD   59.45 (-1.10%)
NFLX   482.10 (-1.26%)
BA   209.39 (+4.89%)
DIS   146.15 (+3.60%)
S&P 500   3,570.70 (+0.37%)
DOW   29,518.92 (+0.87%)
QQQ   290.21 (-0.06%)
AAPL   114.71 (-2.24%)
MSFT   209.97 (-0.20%)
FB   268.42 (-0.47%)
GOOGL   1,725.28 (-0.64%)
AMZN   3,102.18 (+0.09%)
TSLA   519.68 (+6.14%)
NVDA   526.36 (+0.54%)
BABA   270.70 (-0.01%)
CGC   24.74 (+4.30%)
GE   10.13 (+3.79%)
MU   63.90 (+4.07%)
AMD   85.85 (+1.43%)
T   28.53 (+0.74%)
NIO   54.15 (+9.95%)
F   8.87 (+1.49%)
ACB   7.27 (+1.96%)
GILD   59.45 (-1.10%)
NFLX   482.10 (-1.26%)
BA   209.39 (+4.89%)
DIS   146.15 (+3.60%)
S&P 500   3,570.70 (+0.37%)
DOW   29,518.92 (+0.87%)
QQQ   290.21 (-0.06%)
AAPL   114.71 (-2.24%)
MSFT   209.97 (-0.20%)
FB   268.42 (-0.47%)
GOOGL   1,725.28 (-0.64%)
AMZN   3,102.18 (+0.09%)
TSLA   519.68 (+6.14%)
NVDA   526.36 (+0.54%)
BABA   270.70 (-0.01%)
CGC   24.74 (+4.30%)
GE   10.13 (+3.79%)
MU   63.90 (+4.07%)
AMD   85.85 (+1.43%)
T   28.53 (+0.74%)
NIO   54.15 (+9.95%)
F   8.87 (+1.49%)
ACB   7.27 (+1.96%)
GILD   59.45 (-1.10%)
NFLX   482.10 (-1.26%)
BA   209.39 (+4.89%)
DIS   146.15 (+3.60%)
Log in
NYSE:SNY

Sanofi Stock Forecast, Price & News

$49.78
-0.74 (-1.46 %)
(As of 11/23/2020 01:38 PM ET)
Add
Compare
Today's Range
$49.69
Now: $49.78▼
$50.53
50-Day Range
$45.30
MA: $49.59▼
$51.62
52-Week Range
$37.62
Now: $49.78▼
$55.00
Volume66,252 shs
Average Volume1.70 million shs
Market Capitalization$124.66 billion
P/E Ratio15.90
Dividend Yield2.32%
Beta0.67
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; and Parkinson's Foundation, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Read More
Sanofi logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.2Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.78 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:SNY
Previous Symbol
CUSIPN/A
CIK1121404
Webwww.sanofi.com
Phone33-1-53-77-44-00
Employees100,409

Debt

Debt-to-Equity Ratio0.40
Current Ratio1.22
Quick Ratio0.85

Price-To-Earnings

Trailing P/E Ratio15.90
Forward P/E Ratio16.06
P/E Growth2.41

Sales & Book Value

Annual Sales$39.60 billion
Price / Sales3.15
Cash Flow$5.47 per share
Price / Cash Flow9.10
Book Value$26.11 per share
Price / Book1.91

Profitability

EPS (Most Recent Fiscal Year)$3.13
Net Income$4.28 billion
Net Margins12.20%
Return on Equity18.18%
Return on Assets9.78%

Miscellaneous

Outstanding Shares2,504,140,000
Market Cap$124.66 billion
Next Earnings DateN/A
OptionableOptionable
$49.78
-0.74 (-1.46 %)
(As of 11/23/2020 01:38 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sanofi (NYSE:SNY) Frequently Asked Questions

How has Sanofi's stock price been impacted by Coronavirus (COVID-19)?

Sanofi's stock was trading at $44.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SNY stock has increased by 11.4% and is now trading at $49.91.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Sanofi?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Sanofi.

What stocks does MarketBeat like better than Sanofi?

Wall Street analysts have given Sanofi a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sanofi wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) issued its quarterly earnings results on Thursday, October, 29th. The company reported $1.07 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.02. The business had revenue of $9.48 billion for the quarter, compared to analyst estimates of $9.65 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. Sanofi's revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.92 earnings per share.
View Sanofi's earnings history.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi updated its FY 2020 Pre-Market earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of 7.00-7.14 for the period.

What price target have analysts set for SNY?

11 brokerages have issued 12-month target prices for Sanofi's stock. Their forecasts range from $56.00 to $58.00. On average, they expect Sanofi's share price to reach $57.00 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts' price targets for Sanofi.

Who are some of Sanofi's key competitors?

Some companies that are related to Sanofi include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), AstraZeneca (AZN), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), Commonwealth Bank of Australia (CSLLY), GlaxoSmithKline (GSK) and Zoetis (ZTS).
View all competitors.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Pfizer (PFE), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), The Walt Disney (DIS), AbbVie (ABBV), AT&T (T) and Alibaba Group (BABA).

Who are Sanofi's key executives?

Sanofi's management team includes the following people:
  • Mr. Paul Hudson, CEO & Director (Age 53)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 55)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik C.F.A., CPA, CFA, Head of Investor Relations
  • Ms. Karen Linehan, Exec. VP of Legal Affairs & Gen. Counsel (Age 61)
  • Mr. Dante Beccaria, Global Compliance Officer & VP
  • Mr. Josep Catlla, Head of Communications
  • Mr. Pierre Chancel, Sr. VP of Global Diabetes and Sr. VP of Global Marketing (Age 63)
  • Ms. Natalie Bickford, Exec. VP & Chief People Officer

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.74%), BlackRock Inc. (0.54%), Morgan Stanley (0.14%), Wells Fargo & Company MN (0.07%), Hamlin Capital Management LLC (0.05%) and Cambiar Investors LLC (0.05%).
View institutional ownership trends for Sanofi.

Which institutional investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Chubb Ltd, Brandes Investment Partners LP, OLD Mission Capital LLC, Cambiar Investors LLC, Point72 Asset Management L.P., and LSV Asset Management.
View insider buying and selling activity for Sanofi.

Which institutional investors are buying Sanofi stock?

SNY stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, First Trust Advisors LP, Wells Fargo & Company MN, DekaBank Deutsche Girozentrale, Jag Capital Management LLC, Schonfeld Strategic Advisors LLC, Hamlin Capital Management LLC, and Holloway Wealth Management LLC.
View insider buying and selling activity for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $49.91.

How big of a company is Sanofi?

Sanofi has a market capitalization of $124.98 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. Sanofi employs 100,409 workers across the globe.

What is Sanofi's official website?

The official website for Sanofi is www.sanofi.com.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.